VYGR Pengajuan SEC - Voyager Therapeutics, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	54930082S4XVR0ZWCC74
CIK	1640266

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Voyager Therapeutics, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

September 2, 2025	EX-99.1	Leveraging Genetics to Treat Neurological Diseases Citi 2025 Biopharma Back to School Conference September 2, 2025 Exhibit 99.1 Leveraging Genetics to Treat Neurological Diseases Citi 2025 Biopharma Back to School Conference September 2, 2025 2 \| Forward - Looking Statements This presentation contains forward - looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws . The use of words such as “anticipate,” “e
September 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 2, 2025 Voyager Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 2, 2025 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi
August 6, 2025	EX-99.1	Voyager Reports Second Quarter 2025 Financial and Operating Results - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s dise EXHIBIT 99.1 Voyager Reports Second Quarter 2025 Financial and Operating Results - Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s disease franchise - - 11 partnered programs with potential for $2.6B in development-stage milestone payments - LEXINGTON, Mass., August 6, 20
August 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2025 Voyager Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2025 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi
August 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyage
June 9, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Voyager Therapeutics, Inc.
June 9, 2025	S-8	As filed with the Securities and Exchange Commission on June 9, 2025 As filed with the Securities and Exchange Commission on June 9, 2025 Registration No.
June 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2025 Voyager Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2025 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
May 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyag
May 6, 2025	EX-10.2	Second Amendment to Option and License Agreement, by and between the Company and AstraZeneca Ireland Limited, dated as of March 15, 2025. Exhibit 10.2 Second Amendment to Option and License Agreement This Second Amendment to Option and License Agreement (this “Amendment”) is entered into and made effective as of March 15, 2025 (the “Amendment Effective Date”) by and between (i) Voyager Therapeutics, Inc., a Delaware corporation having its principal place of business at 75 Hayden Avenue, Lexington, MA 02421 (“Voyager”), and (ii) Astr
May 6, 2025	EX-99.1	Voyager Reports First Quarter 2025 Financial and Operating Results - Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e1 EXHIBIT 99.1 Voyager Reports First Quarter 2025 Financial and Operating Results - Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg - - Recent Voyager data on VY7523 and VY1706 presented at AD/PD™ 2025 continue to support tau as next critical target in Alzheime
May 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2025 Voyager Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2025 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
May 6, 2025	EX-10.1	Form of Performance Restricted Stock Unit Award Agreement. Exhibit 10.1 PERFORMANCE RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER VOYAGER THERAPEUTICS, INC. 2015 STOCK OPTION AND INCENTIVE PLAN Pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Voyager Therapeutics, Inc. (the “Company”) hereby grants an award of the number of Performance Restricted Stock Unit
April 23, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14
April 23, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin
March 11, 2025	EX-99.1	Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - A EXHIBIT 99.1 Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging d
March 11, 2025	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Voyager Securities Corporation Massachusetts
March 11, 2025	EX-19.1	Amended and Restated Insider Trading Policy Exhibit 19.1 VOYAGER THERAPEUTICS, INC. Amended and Restated Insider Trading Policy 1. Background and purpose 1.1Why Have We Adopted This Insider Trading Policy? The federal securities laws prohibit any member of the Board of Directors (a “Director”), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the “Exchange Act”), an “executive officer”), or employee of Voyager
March 11, 2025	S-8	As filed with the Securities and Exchange Commission on March 11, 2025 As filed with the Securities and Exchange Commission on March 11, 2025 Registration No.
March 11, 2025	10-K	UNITED STATES Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc.
March 11, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Voyager Therapeutics, Inc.
March 11, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2025 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi
February 11, 2025	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 11, 2025 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi
November 14, 2024	SC 13G/A	VYGR / Voyager Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-vygr093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 92915B106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the
November 14, 2024	SC 13G/A	VYGR / Voyager Therapeutics, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 vygr13ga4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr
November 12, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 12, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi
November 12, 2024	EX-10.2	First Amendment to Option and License Agreement, by and between Registrant and AstraZeneca Ireland Limited, dated September 30, 2024. Exhibit 10.2 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. First Amendment to Option and License Agreement This First Amendment to Option and License Agreement (this “Amendment”) is entered into and made effective as o
November 12, 2024	EX-10.1	First Amendment to Option and License Agreement, by and between Registrant and Novartis Pharma AG, dated September 3, 2024. Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. EXECUTION VERSION CONFIDENTIAL FIRST AMENDMENT TO OPTION AND LICENSE AGREEMENT This First Amendment to Option and License Agreement (this “Amendment”) is enter
November 12, 2024	EX-99.1	Voyager Reports Third Quarter 2024 Financial and Operating Results –Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025– –Recent third-party cl EXHIBIT 99.1 Voyager Reports Third Quarter 2024 Financial and Operating Results –Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025– –Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide support for use of an antibody to target
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 V
September 5, 2024	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 3, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi
August 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2024 Voyager Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 6, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi
August 6, 2024	EX-10.1	First Amendment to Collaboration Agreement, by and between Registrant and Neurocrine Biosciences, Inc., dated April 3, 2024. Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. FIRST AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This FIRST AMENDMENT TO THE COLLABORATION AND LICENSE AGREEMENT (this“Amendment”) is effective as of Apr
August 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyage
August 6, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Voyager Therapeutics, Inc.
August 6, 2024	S-8	As filed with the Securities and Exchange Commission on August 6, 2024 As filed with the Securities and Exchange Commission on August 6, 2024 Registration No.
August 6, 2024	EX-99.1	Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results – Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer’s disease – – Three EXHIBIT 99.1 Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results – Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer’s disease – – Three CNS gene therapy programs on track for INDs in 2025 following development candidate nominations for GBA1 and FA programs and pre-IND mee
June 13, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 11, 2024 Voyager Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 11, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissio
June 13, 2024	EX-10.1	Employment Agreement, by and between Voyager Therapeutics, Inc. and Nathan Jorgensen, Ph.D., M.B.A., effective as of July 8, 2024. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made as of July 8, 2024 (the “Effective Date”) by and between (i) Voyager Therapeutics, Inc., a Delaware corporation with an address at 75 Hayden Avenue, Lexington, MA 02421 (the “Company”) and (ii) Nathan Jorgensen, Ph.D., MBA, an individual with an address at [**] (the “Executive”). 1.            Employment. The Co
June 6, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 5, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
May 16, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
May 13, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 13, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
May 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyag
May 13, 2024	EX-99.1	Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results – Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose t EXHIBIT 99.1 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results – Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer’s disease; expect to begin single ascending dose trial in the coming weeks – – Development candidates selected for Neurocrine-partnered GBA1 and Friedreich’s Ataxia gene therapy programs;
May 13, 2024	EX-10.4	Consulting Agreement by and between the Registrant and Peter P. Pfreundschuh, dated as of May 6, 2024 Exhibit 10.4 Execution Version CONSULTING AGREEMENT THIS AGREEMENT (together with the attached Services Form, the “Agreement”), is entered into as of May 6, 2024 (the “Effective Date”), by and between Peter P. Pfreundschuh, an individual (the “Consultant”), and Voyager Therapeutics, Inc., a Delaware corporation located at 75 Hayden Avenue, Lexington, MA 02421 (hereinafter “Voyager”). WHEREAS, Voya
May 13, 2024	EX-10.1	Amendment No. 4 to Consulting Agreement by and between the Registrant and Dinah Sah, Ph.D., dated as of February 1, 2024. Exhibit 10.1 AMENDMENT NO. 4 TO CONSULTING AGREEMENT This Amendment No. 4 to Consulting Agreement (this “Amendment”) effective as of February 1, 2024 (“Amendment Effective Date”) is entered into by and between (i) Voyager Therapeutics, Inc., a Delaware corporation with an office located at 75 Hayden Avenue, Lexington, MA 02421 (“Voyager”) and (ii) Dinah Sah, Ph.D., an individual residing at [**] (
April 25, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14
April 25, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin
April 2, 2024	EX-10.1	Transition, Separation and Release of Claims Agreement, by and between the Registrant and Peter P. Pfreundschuh, dated April 1, 2024. Exhibit 10.1 Execution Version TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Transition, Separation and Release of Claims Agreement (this “Agreement”) is made as of the Agreement Effective Date (as defined below) by and between Voyager Therapeutics, Inc. (the “Company”) and Peter P. Pfreundschuh (“Executive”) (together, the “Parties”). WHEREAS, the Company and Executive are parties t
April 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2024 Voyager Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi
March 13, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 29, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi
March 13, 2024	EX-10.1	Employment Agreement, by and between the Registrant and Toby Ferguson, M.D., Ph.D., dated as of February 29, 2024. Exhibit 10.1 Execution Version EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made as of February 29, 2024 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Toby Ferguson, M.D., Ph.D. (the “Executive”). 1.            Employment. The Company and the Executive desire that the Executive be employed as the Company’s Chief Medical Officer. The em
February 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2024 Voyager Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi
February 28, 2024	S-8	As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No.
February 28, 2024	EX-10.45	Investor Agreement by and between Registrant and Novartis Pharma AG, dated December 28, 2023 Exhibit 10.45 EXECUTION VERSION INVESTOR AGREEMENT By and Between NOVARTIS PHARMA AG AND VOYAGER THERAPEUTICS, INC. Dated as of December 28, 2023 TABLE OF CONTENTS 1. Definitions 1 2. Restrictions on Beneficial Ownership 5 3. Restrictions on Dispositions 6 3.1 Lock-Up 6 3.2 Certain Tender Offers 7 3.3 Sale Limitations 7 3.4 Offering Lock-Up 7 3.5 Transactions for Personal Account; Change of Contro
February 28, 2024	EX-10.46	Amendment No. 2 to the Consulting Agreement, by and between the Registrant and Dinah Sah, Ph.D., dated June 27, 2022 Exhibit 10.46 AMENDMENT NO. 2 CONSULTING AGREEMENT Amendment No. 2 (this “Amendment”) to the Consulting Agreement, between Dinah Sah (“Consultant”) and Voyager Therapeutics, Inc. (“Voyager”) effective as of June 28, 2019 (the “Effective Date”) as amended by Amendment No. 1 to the Consulting Agreement, effective as of September 16, 2019 (together, the “Agreement”), is entered into as of June 27, 20
February 28, 2024	EX-10.44	Stock Purchase Agreement by and between Registrant and Novartis Pharma AG, dated December 28, 2023 Exhibit 10.44 EXECUTIBE VERSION STOCK PURCHASE AGREEMENT By and Between NOVARTIS PHARMA AG AND VOYAGER THERAPEUTICS, INC. Dated as of December 28, 2023 TABLE OF CONTENTS Page 1. Definitions 1 1.1 Defined Terms 1 1.2 Additional Defined Terms 4 2. Purchase and Sale of Common Stock 5 3. Closing Date; Deliveries 6 3.1 Closing Date 6 3.2 Deliveries 6 4. Representations and Warranties of the Company 6 4
February 28, 2024	EX-97.1	Compensation Recovery Policy Exhibit 97.1 VOYAGER THERAPEUTICS, INC. Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Voyager Therapeutics, Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”). This Policy is effective as of October 2, 2023 (the “Effective Date”). 1.Definitions (a)“Accounting Restatement” means a requirement that the Company prepare an acco
February 28, 2024	EX-10.43	License and Collaboration Agreement by and between Registrant and Novartis Pharma AG, dated December 28, 2023 Exhibit 10.43 Execution Version Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AND COLLABORATION AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND NOVARTIS PHARMA, AG December 28, 2023 TABLE OF CONTENTS Pa
February 28, 2024	EX-10.47	Amendment No. 3 to the Consulting Agreement, by and between the Registrant and Dinah Sah, Ph.D., dated May 1, 2023 Exhibit 10.47 AMENDMENT NO. 3 TO CONSULTING AGREEMENT This Amendment No. 3 to Consulting Agreement (this ”Amendment”) effective as of May 1, 2023 (“Amendment Effective Date”) is entered into by and between (i) Voyager Therapeutics, Inc., a Delaware corporation with an office located at 64 Sidney Street, Cambridge, MA 02139 (“Voyager”) and (ii) Dinah Sah, Ph.D., an individual residing at 15 Huckleb
February 28, 2024	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Voyager Securities Corporation Massachusetts
February 28, 2024	10-K	UNITED STATES Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc.
February 28, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Voyager Therapeutics, Inc.
February 28, 2024	EX-99.1	Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results – Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $1 EXHIBIT 99.1 Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results – Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering – – Strong cash position and anticipated milestones/reimbursements provide runway into 2027, potentially enabl
February 14, 2024	SC 13G/A	VYGR / Voyager Therapeutics, Inc. / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d791499dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* Voyager Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement)
February 14, 2024	SC 13G/A	VYGR / Voyager Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-vygr123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the a
February 13, 2024	SC 13G/A	VYGR / Voyager Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02243-voyagertherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Voyager Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 92915B106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t
January 8, 2024	EX-99.1	Voyager Therapeutics, Inc. • 75 Hayden Avenue, Lexington, MA 02421 • 857.259.5340 • voyagertherapeutics.com Exhibit 99.1 Voyager Therapeutics Announces Pricing of Public Offering LEXINGTON, Mass., JANUARY 4, 2024 – Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the pricing of an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of $9.00 per share, and, to investors who so choo
January 8, 2024	EX-4.1	Form of Pre-Funded Warrant Exhibit 4.1 VOYAGER THERAPEUTICS, Inc. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: January [], 2024 Voyager Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registered assigns (the “Holde
January 8, 2024	EX-1.1	Underwriting Agreement, dated January 4, 2024, by and among Voyager Therapeutics, Inc. and Citigroup Global Markets Inc. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein. Exhibit 1.1 7,777,778 Shares Pre-Funded Warrants to Purchase 3,333,333 Shares Voyager Therapeutics, Inc. Common Stock UNDERWRITING AGREEMENT January 4, 2024 Citigroup Global Markets Inc. Guggenheim Securities, LLC As Representatives of the several Underwriters c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 c/o Guggenheim Securities, LLC 330 Madison Ave New York, Ne
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 3, 2024 Voyager Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 3, 2024 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commiss
January 8, 2024	424B5	7,777,778 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 3,333,333 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-268240 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED NOVEMBER 15, 2022) 7,777,778 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 3,333,333 Shares of Common Stock We are offering 7,777,778 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase up
January 4, 2024	424B5	SUBJECT TO COMPLETION, DATED JANUARY 4, 2024 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.
January 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 28, 2023 Voyager Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 28, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi
December 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 6, 2023 Voyager Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 6, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis
December 6, 2023	EX-99.1	Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program - IND filing expected in mid-2025 - Exhibit 99.1 Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program - IND filing expected in mid-2025 - LEXINGTON, Mass., DECEMBER 6, 2023 – Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead develop
November 6, 2023	EX-99.1	Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results - GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on tr EXHIBIT 99.1 Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results - GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on track for development candidate selection by end of year – - Conference call at 4:30 p.m. ET today - LEXINGTON, Mass., November 6, 2023 – V
November 6, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 V
November 6, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis
August 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2023 Voyager Therapeut UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commiss
August 16, 2023	EX-10.1	First Amendment to Lease Agreement, by and between Registrant and LS 75 Hayden, LLC, dated August 11, 2023. Exhibit 10.1 75 HAYDEN AVENUE LEXINGTON, MASSACHUSETTS 02421 (the “Building”) FIRST AMENDMENT (“First Amendment”) EFFECTIVE DATE: August 11, 2023 LANDLORD: LS 75 HAYDEN, LLC, a Delaware limited liability company, as successor-in-interest to HCP/King 75 Hayden LLC, a Delaware limited liability company TENANT: VOYAGER THERAPEUTICS, INC., a Delaware corporation EXISTING PREMISES: Areas on the first (
August 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyage
August 3, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 3, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi
August 3, 2023	EX-99.1	Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results - Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer’s disease portfolio - - Executed license agreement with Sangamo for pr EXHIBIT 99.1 Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results - Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer’s disease portfolio - - Executed license agreement with Sangamo for prion disease treatment - - Presented validating preclinical results including increased brain transduction of IV-administered TRACER™ caps
July 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 5, 2023 Voyager Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 5, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
July 10, 2023	EX-10.1	Employment Agreement by and between the Registrant and Jacquelyn Fahey Sandell, effective as of July 5, 2023 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made as of July 5, 2023 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Jacquelyn Fahey Sandell (the “Executive”). 1.            Employment. The Company and the Executive desire that the Executive be employed as the Company’s Chief Legal Officer. The employment relationship betwee
June 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 6, 2023 Voyager Therapeutics UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 6, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
May 9, 2023	EX-10.5	Consulting Agreement, by and between the Registrant and Robert W. Hesslein, dated April 28, 2023 Exhibit 10.5 CONSULTING AGREEMENT THIS AGREEMENT (together with the attached Accounting of Services Form, the “Agreement”), is entered into as of April 29, 2023 (the “Effective Date”), by and between Robert W. Hesslein, an individual (the “Consultant”), and Voyager Therapeutics, Inc., a Delaware corporation located at 64 Sidney Street, Cambridge, MA 02139 (hereinafter “Voyager”). WHEREAS, Voyager
May 9, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
May 9, 2023	EX-99.1	Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results - Neurocrine Biosciences strategic collaboration and Novartis license option exercise demonstrate Voyager pipeline and platform value and strengthen balance sheet - - Alz EXHIBIT 99.1 Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results - Neurocrine Biosciences strategic collaboration and Novartis license option exercise demonstrate Voyager pipeline and platform value and strengthen balance sheet - - Alzheimer’s disease franchise advances: selected lead candidate for anti-tau antibody program; IND submission on track for first half of 202
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2023 Voyager Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyag
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 Voyager Therapeutics, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
April 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin
April 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2023 Voyager Therapeuti UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi
March 7, 2023	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Voyager Securities Corporation Massachusetts
March 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 7, 2023 Voyager Therapeutic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 7, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissio
March 7, 2023	EX-10.45	Collaboration and License Agreement by and between the Registrant and Neurocrine Biosciences, Inc., dated as of January 8, 2023 Exhibit 10.45 EXECUTION COPY CONFIDENTIAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENT by and between VOYAGER THERAPEUTICS, INC. AND NEUROCRINE BIOSCIENCES, INC. EXECUTION COPY CONF
March 7, 2023	10-K	UNITED STATES Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc.
March 7, 2023	EX-10.43	Patent and Know-How Licence between the Registrant and Touchlight IP Limited, dated as of November 3, 2022 Exhibit 10.43 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. DATED 3NOVEMBER 2022 PATENT AND KNOW-HOW LICENCE BETWEEN TOUCHLIGHT IP LIMITED AND VOYAGER THERAPEUTICS, INC. This agreement is dated 3 November 2022 Parties
March 7, 2023	EX-10.36	Option and License Agreement by and between the Registrant and Novartis Pharma AG, dated March 4, 2022 Exhibit 10.36 Execution Version Confidential Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. OPTION AND LICENSE AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND NOVARTIS PHARMA, A.G. March 4, 2022 TABLE OF CONTENT
March 7, 2023	EX-10.46	Amended and Restated Investor Agreement by and between the Registrant and Neurocrine Biosciences, Inc., dated as of January 8, 2023 Exhibit 10.46 EXECUTION VERSION AMENDED AND RESTATED INVESTOR AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. AND VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 TABLE OF CONTENTS 1. Definitions 1 2. Restrictions on Beneficial Ownership 6 3. Restrictions on Dispositions 7 3.1 Lock-Up 7 3.2 Certain Tender Offers 7 3.3 Sale Limitations 7 3.4 Offering Lock-Up 8 3.5 Transactions for Perso
March 7, 2023	EX-FILING FEES	Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Voyager Therapeutics, Inc.
March 7, 2023	EX-10.44	Stock Purchase Agreement by and between the Registrant and Neurocrine Biosciences, Inc., dated as of January 8, 2023 Exhibit 10.44 EXECUTION VERSION STOCK PURCHASE AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. AND VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 TABLE OF CONTENTS Page 1. Definitions 1 1.1 Defined Terms 1 1.2 Additional Defined Terms 4 2. Purchase and Sale of Common Stock 5 3. Closing Date; Deliveries 5 3.1 Closing Date 5 3.2 Deliveries 5 4. Representations and Warranties of the Com
March 7, 2023	EX-99.1	Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results - Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACERTM novel capsid platform through tr EXHIBIT 99.1 Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results - Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACERTM novel capsid platform through transactions with Pfizer and Novartis - - Partnering momentum continues into 2023 with $175 million payment associated with Neurocrine Bios
March 7, 2023	S-8	As filed with the Securities and Exchange Commission on March 7, 2023 As filed with the Securities and Exchange Commission on March 7, 2023 Registration No.
February 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Voyager Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi
February 24, 2023	SC 13D/A	VYGR / Voyager Therapeutics Inc / Neurocrine Biosciences Inc - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) Kevin C. Gorman, Ph.D. Chief Executive Officer Neurocrine Biosciences, Inc. 12780 El Camino Real San Die
February 24, 2023	EX-99.1	AMENDED AND RESTATED INVESTOR AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 EX-99.1 Exhibit 99.1 AMENDED AND RESTATED INVESTOR AGREEMENT By and Between NEUROCRINE BIOSCIENCES, INC. AND VOYAGER THERAPEUTICS, INC. Dated as of January 8, 2023 TABLE OF CONTENTS 1. Definitions 1 2. Restrictions on Beneficial Ownership 6 3. Restrictions on Dispositions 7 3.1 Lock-Up 7 3.2 Certain Tender Offers 7 3.3 Sale Limitations 7 3.4 Offering Lock-Up 8 3.5 Transactions for
February 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2023 Voyager Therape UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 22, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi
February 23, 2023	EX-10.1	Transition, Separation and Release of Claims Agreement, by and between the Company and Robert W. Hesslein, dated February 22, 2023. Exhibit 10.1 Execution Version TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Transition, Separation and Release of Claims Agreement (this “Agreement”) is made as of the Agreement Effective Date (as defined below) by and between Voyager Therapeutics, Inc. (the “Company”) and Robert W. Hesslein (“Executive”) (together, the “Parties”). WHEREAS, the Company and Executive are parties to t
February 14, 2023	SC 13G/A	VYGR / Voyager Therapeutics Inc / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d420693dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Voyager Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement)
February 14, 2023	SC 13G	VYGR / Voyager Therapeutics Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 9, 2023	SC 13G/A	VYGR / Voyager Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02209-voyagertherapeuticsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Voyager Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 92915B106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box
January 13, 2023	SC 13G/A	VYGR / Voyager Therapeutics Inc / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 voyagerthera13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) January 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the
January 9, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2023 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commiss
December 14, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 13, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi
November 15, 2022	424B3	Up to $75,000,000 Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(3)? ?Registration No. 333-268240? PROSPECTUS ? Up to $75,000,000 Common Stock ? We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our common s
November 10, 2022	CORRESP	VOYAGER THERAPEUTICS, INC. 64 Sidney Street Cambridge, MA 02139 VOYAGER THERAPEUTICS, INC. 64 Sidney Street Cambridge, MA 02139 November 10, 2022 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Voyager Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-268240 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities A
November 8, 2022	EX-4.4	Form of Senior Indenture Exhibit 4.4 VOYAGER THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b)
November 8, 2022	S-3	As filed with the Securities and Exchange Commission on November 8, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 8, 2022 Registration No.
November 8, 2022	EX-4.6	Form of Senior Note Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE
November 8, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2022 Voyager Therapeu UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis
November 8, 2022	EX-1.2	Sales Agreement, by and between the Registrant and Cowen and Company, LLC, dated November 8, 2022 Exhibit 1.2 Voyager Therapeutics, Inc. $75,000,000 Common STOCk SALES AGREEMENT November 8, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Voyager Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that,
November 8, 2022	EX-4.7	Form of Subordinated Note Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE
November 8, 2022	EX-4.5	Form of Subordinated Indenture Exhibit 4.5 VOYAGER THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02
November 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 V
November 8, 2022	EX-99.1	Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results - Voyager’s TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TR EXHIBIT 99.1 Voyager Therapeutics Reports Third Quarter 2022 Financial and Operating Results - Voyager’s TRACERTM capsid platform validated by Pfizer option exercise - - Data characterizing a novel receptor and demonstrating low-dose potential further validate TRACER - - Pipeline programs advancing; development candidate selections for lead programs expected Q4 2022 to H1 2023 - - Conference call
November 8, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Voyager Therapeutics, Inc.
October 4, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 4, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commiss
September 7, 2022	EX-10.2	Second Amended and Restated Employment Agreement by and between the Registrant and Todd Carter, Ph.D., effective as of September 7, 2022 Exhibit 10.2 ?? SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT ? This Second Amended and Restated Employment Agreement (this ?Agreement?) is made as of September?7, 2022 (the ?Effective Date?) by and between Voyager Therapeutics,?Inc. (the ?Company?) and Todd Carter, Ph.D. (the ?Executive?). ? WHEREAS, the Company and the Executive are parties to a certain Amended and Restated Employment Agreeme
September 7, 2022	EX-10.1	Employment Agreement by and between the Registrant and Peter Pfreundschuh, effective as of September 7, 2022 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made as of September 7, 2022 (the ?Effective Date?) by and between Voyager Therapeutics, Inc. (the ?Company?) and Peter Pfreundschuh (the ?Executive?). 1.????????????Employment. The Company and the Executive desire that the Executive be employed as the Company?s Chief Financial Officer. The employment relationship be
September 7, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 7, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi
August 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 4, 2022	EX-99.1	Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1-ALS, each program employing e EXHIBIT 99.1 Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results ? Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1-ALS, each program employing efficient paths to human proof of biology ? Targeting development candidate selection for priority programs in 2022 and H1 2023 ? Cross
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): August 4, 2022 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other jurisd
July 28, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 27, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissio
June 23, 2022	EX-10.1	Lease Termination Agreement by and between the Registrant and BRE-BMR Pilgrim & Sidney LLC, dated as of June 22, 2022 Exhibit 10.1 LEASE TERMINATION AGREEMENT THIS LEASE TERMINATION AGREEMENT (this ?Agreement?) is entered into as of this 22nd day of June, 2022 (?Effective Date?), by and between BRE-BMR Pilgrim & Sidney LLC, a Delaware limited liability company, as successor-in-interest to UP 45/75 Sidney Street, LLC (?Landlord?) and Voyager Therapeutics, Inc., a Delaware corporation (?Tenant?). RECITALS A.???????
June 23, 2022	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 22, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissio
June 23, 2022	EX-10.2	Sublease Termination Agreement by and between the Registrant and BioNTech US, Inc., dated as of June 22, 2022 Exhibit 10.2 SUBLEASE TERMINATION AGREEMENT THIS SUBLEASE TERMINATION AGREEMENT (this ?Agreement?) is entered into as of this 22nd day of June, 2022 (?Effective Date?), by and between Voyager Therapeutics, Inc., a Delaware corporation (?Voyager?), and BioNTech US Inc., a Delaware corporation (?BioNTech?). RECITALS A.??????????WHEREAS, UP 45/75 Sidney Street, LLC, as predecessor to BRE-BMR Pilgrim
June 7, 2022	EX-10.1	Consulting Agreement by and between the Registrant and Glenn Pierce, M.D., Ph.D., effective as of June 6, 2022 Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (including the exhibits attached hereto, ?Agreement?), is entered into as of June 6, 2022 (?Effective Date?), by and between (i) Voyager Therapeutics, Inc., a Delaware corporation with an office at 64 Sidney Street, Cambridge, MA 02139 (?Voyager?) and (ii) Dr. Glenn Pierce, M.D., Ph.D., with an address of (?Consultant?). WHEREAS, Voyager
June 7, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 2, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
May 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): May 4, 2022 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other jurisdict
May 4, 2022	EX-99.1	Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel EXHIBIT 99.1 Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results ? Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACERTM AAV9 and AAV5-derived capsids ? Preclinical data to be presented at the ASGCT Annual Meeting to demonstrate reduction of tumor
May 4, 2022	EX-10.3	Option and License Agreement by and between the Registrant and Novartis Pharma AG, dated March 4, 2022. Execution Version Confidential Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.
May 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 26, 2022	SC 13G/A	VYGR / Voyager Therapeutics Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) April 21, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
April 21, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Def
April 21, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14
April 20, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 14, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi
March 22, 2022	EX-10.1	Employment Agreement, by and between the Registrant and Alfred Sandrock, M.D., Ph.D., effective as of March 22, 2022. Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made as of March 22, 2022 (the ?Effective Date?) by and between Voyager Therapeutics, Inc. (the ?Company?) and Alfred Sandrock, M.D., Ph.D. (the ?Executive?). 1. Employment. The Company and the Executive desire that the Executive be employed as the Company?s President and Chief Executive Officer. The employment relat
March 22, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 19, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi
March 8, 2022	EX-FILING FEES	Calculation of Filing Fee Tables. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Voyager Therapeutics, Inc.
March 8, 2022	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT ? ? ? Name of Entity State/Country of Organization ? ? ? Voyager Securities ? Corporation Massachusetts ?
March 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): March 8, 2022 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other jurisdi
March 8, 2022	10-K	UNITED STATES Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? ? FORM 10-K ? ? (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number: 001-37625 ? ? Voyager Therapeutics, Inc.
March 8, 2022	EX-99.1	Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results License option agreement with Novartis for target-specific access to TRACERTM next-generation AAV capsids for potential use with three CNS targets plus opt EXHIBIT 99.1 Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results ? License option agreement with Novartis for target-specific access to TRACERTM next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets ? Novartis agreement marks second recent major transaction to leverage Voyager?s TRAC
March 8, 2022	EX-10.39	Employment Agreement, by and between the Registrant and Julie Burek, dated as of October 1, 2021 Exhibit 10.39 ? ? EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made as of October 1, 2021 (the ?Agreement Date?) by and between Voyager Therapeutics, Inc. (the ?Company?) and Julie Burek (the ?Executive?). 1.Employment. The Company and the Executive acknowledge and agree that: (a) the Executive has been employed by the Company since April 2, 2018 (the ?Employment Date?), an
March 8, 2022	EX-10.37	Separation and Release of Claims Agreement by and between the Registrant and Allison Dorval, effective December 13, 2021 Exhibit 10.37 SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Separation and Release of Claims Agreement (this ?Agreement?) is made as of the Agreement Effective Date (as defined below) by and between Voyager Therapeutics, Inc. (the ?Company?) and Allison Dorval (?Executive?) (together, the ?Parties?). WHEREAS, the Company and Executive are parties to the Employment Agreement dated as of November
March 8, 2022	S-8	As filed with the Securities and Exchange Commission on March 8, 2022 As filed with the Securities and Exchange Commission on March 8, 2022 Registration No.
March 8, 2022	EX-10.38	Consulting Agreement by and between the Registrant and Allison Dorval, dated as of November 26, 2021 Exhibit 10.38 CONSULTING AGREEMENT ? THIS AGREEMENT (together with the attached Accounting of Services Form, the ?Agreement?), is entered into as of November 26, 2021 (the ?Effective Date?), by and between Allison Dorval, an individual (the ?Consultant?), and Voyager Therapeutics, Inc., a Delaware corporation located at 75 Sidney Street, Cambridge, MA 02139 (hereinafter ?Voyager?). ? WHEREAS, Voya
February 15, 2022	SC 13G/A	VYGR / Voyager Therapeutics Inc / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 15, 2022	EX-99.A	AGREEMENT Exhibit A AGREEMENT The undersigned agree that this Amendment No. 2 to Schedule 13G dated February 14, 2022 relating to the Common Stock, $0.001 par value, of Voyager Therapeutics, Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd
February 14, 2022	SC 13G/A	VYGR / Voyager Therapeutics Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t
February 11, 2022	SC 13G/A	VYGR / Voyager Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this
February 10, 2022	SC 13G/A	VYGR / Voyager Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Voyager Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 92915B106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi
February 3, 2022	EX-10.2	Amended and Restated Employment Agreement, by and between the Registrant and Robin Swartz, effective as of February 7, 2022 Exhibit 10.2 EXECUTION VERSION AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this ?Agreement?) is made as of February 7, 2022 (the ?Effective Date?) by and between Voyager Therapeutics, Inc. (the ?Company?) and Robin Swartz (the ?Executive?). WHEREAS, the Company and the Executive are parties to a certain Employment Agreement dated January 11, 2021 (the
February 3, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 1, 2022 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis
February 3, 2022	EX-10.1	Consulting Agreement by and between the Registrant and Alfred Sandrock, effective as of February 7, 2022 Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (including the exhibits attached hereto, this ?Agreement?), effective as of February 7, 2022 (the ?Effective Date?), is entered into by and between (i) Voyager Therapeutics, Inc., a Delaware corporation with an office at 75 Sidney Street, Cambridge, MA 02139 (?Voyager?) and (ii) Alfred Sandrock, Jr., M.D., Ph.D., an individual residing at
November 19, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 16, 2021 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi
November 2, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 2, 2021	EX-10.2	Option and License Agreement, by and between the Registrant and Pfizer Inc., dated October 1, 2021 Exhibit 10.2 EXECUTION VERSION Confidential Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. OPTION AND LICENSE AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND PFIZER INC. October 1, 2021 ? ? ? ? TABLE OF CONTENTS
November 2, 2021	EX-99.1	Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results License option agreement with Pfizer provides Voyager $30M up front and up to $600M in potential exercise fees and milestones payments plus royalties in exchange for acce EXHIBIT 99.1 Voyager Therapeutics Reports Third Quarter 2021 Financial and Operating Results ? License option agreement with Pfizer provides Voyager $30M up front and up to $600M in potential exercise fees and milestones payments plus royalties in exchange for access to TRACER? novel capsids for use with two Pfizer transgenes in neurologic and cardiovascular disease ? TRACER platform identifies AA
November 2, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): November 2, 2021 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other juri
November 2, 2021	EX-10.1	Sublease Agreement, by and between Registrant and BioNTech US Inc., dated September 3, 2021 SUBLEASE AGREEMENT ? ? THIS SUBLEASE AGREEMENT (this ?Sublease?) is made and entered into as of September 3, 2021 (the ?Effective Date?), by and between VOYAGER THERAPEUTICS, INC.
October 22, 2021	SC 13G	VYGR / Voyager Therapeutics Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) October 12, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
October 6, 2021	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 1, 2021 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commiss
August 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): August 9, 2021 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other jurisd
August 9, 2021	EX-99.1	Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACERTM AAV Capsid and Vectorized Antibody Platform Technologies Proprietary AAV capsids to power second-generation efforts in Huntington’s disease and ALS, pre-cli EXHIBIT 99.1 ? Voyager Therapeutics Transforms Pipeline and Increases Investment in Next-Generation TRACERTM AAV Capsid and Vectorized Antibody Platform Technologies Proprietary AAV capsids to power second-generation efforts in Huntington?s disease and ALS, pre-clinical programs in spinal muscular atrophy and diseases linked to GBA1 mutations Increased platform investment to expand discovery of no
August 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 8, 2021	EX-10.1	Amendment No. 1 to Employment Agreement, by and between the Registrant and Glenn Pierce, dated June 7, 2021 Exhibit 10.1 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (this ?Amendment?) is made as of June 7, 2021 (the ?Amendment Effective Date?) by and between Voyager Therapeutics, Inc. (the ?Company?) and Glenn Pierce (the ?Executive?). Any capitalized terms used but not defined in this Amendment shall have the meanings ascribed to such terms in the Agreement (as
June 8, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 3, 2021 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
May 19, 2021	EX-10.1	Transition, Separation and Release of Claims Agreement, by and between the Registrant and G. Andre Turenne, dated May 19, 2021. Exhibit 10.1 EXECUTION COPY TRANSITION, SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Transition, Separation and Release of Claims Agreement (the ?Agreement?) is made as of the Agreement Effective Date (as defined below) by and between Voyager Therapeutics, Inc. (the ?Company?) and Gaetan Andre Turenne (?Executive?) (together, the ?Parties?). WHEREAS, the Company and Executive are parties to the
May 19, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2021 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
May 19, 2021	EX-10.3	Employment Agreement, by and between the Registrant and Glenn Pierce, M.D., Ph.D., dated May 19, 2021 Exhibit 10.3 EXECUTION COPY EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made as of May 19, 2021 (the ?Effective Date?) by and between Voyager Therapeutics, Inc. (the ?Company?) and Glenn Pierce (the ?Executive?). 1. Employment. The Company and the Executive desire that the Executive be employed as the Company?s interim Chief Scientific Officer. The employment relationship
May 19, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
May 19, 2021	EX-10.2	Employment Agreement, by and between the Registrant and Michael Higgins, dated May 19, 2021 EX-10.2 3 tm2116931d1ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 EXECUTION COPY EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made as of May 19, 2021 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Michael Higgins (the “Executive”). 1. Employment. The Company and the Executive desire that the Executive be employed as the Company’s interim Presid
May 10, 2021	EX-99.1	Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates - On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington’s disease in the fourth quarter of 2021 - 8 presentations at American Society of Gene and Cell EXHIBIT 99.1 Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates ? - On track to initiate Phase 1/2 trial of VY-HTT01 for Huntington?s disease in the fourth quarter of 2021 - 8 presentations at American Society of Gene and Cell Therapy (ASGCT) conference, including new data on next generation blood brain barrier penetrant capsids - Virtual investor and analyst
May 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): May 10, 2021 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other jurisdic
May 10, 2021	10-Q	Quarterly Report - 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 22, 2021	DEF 14A	- DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule
February 26, 2021	S-8	Form S-8, File No. 333-253549 As filed with the Securities and Exchange Commission on February 25, 2021 Registration No.
February 25, 2021	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ? ? FORM 10-K ? ? (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? For the transition period from to Commission File Number: 001-37625 ? ? Voyager Therapeutics, Inc.
February 25, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): February 25, 2021 ? ? Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? ? Delaware ? 001-37625 ? 46-3003182 (State or other jur
February 25, 2021	EX-10.40	AMENDMENT NO. 2 CONSULTING AGREEMENT EX-10.40 2 vygr-20201231xex10d40.htm EX-10.40 Exhibit 10.40 AMENDMENT NO. 2 TO CONSULTING AGREEMENT This Amendment No. 02 TO CONSULTING AGREEMENT (“Amendment”) is entered into as of August 1, 2020 (the “Amendment Effective Date”) between Steven M. Paul, M.D. (“Company”) and Voyager Therapeutics, Inc. (“Voyager”) and relates to the Agreement referred to below. WHEREAS, the parties previously entere
February 25, 2021	EX-21.1	Subsidiaries of the Registrant. EX-21.1 3 vygr-20201231xex21d1.htm EX-21.1 Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Voyager Securities Corporation Massachusetts
February 25, 2021	EX-99.1	Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates ● Expects to Provide Complete Response to FDA Requests on IND Application for VY-HTT01 for Huntington’s Disease in the First Half of 2021 ● Conti EXHIBIT 99.1 Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates ● Expects to Provide Complete Response to FDA Requests on IND Application for VY-HTT01 for Huntington’s Disease in the First Half of 2021 ● Continues to Progress Pipeline and Platform Activities with Expected Presentations of Data in the First Half of 2021 CAMBRIDGE, Mass., Februar
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 12, 2021	SC 13G/A	United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) D SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to w
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Voyager Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 92915B106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is fi
February 2, 2021	8-K	Termination of a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 2, 2021 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis
January 15, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 15, 2021 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis
November 9, 2020	EX-10.1	First Amendment to Amended and Restated Option and License Agreement with Genzyme Corporation, dated September 20, 2020 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.
November 9, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625
November 9, 2020	EX-99.1	Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates Plans to present three-year Phase 1b results of VY-AADC (NBIb-1817) in patients with Parkinson’s disease at the Movement Disorder Society (MDS) Virtual Congress EXHIBIT 99.1 Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates Plans to present three-year Phase 1b results of VY-AADC (NBIb-1817) in patients with Parkinson’s disease at the Movement Disorder Society (MDS) Virtual Congress 2020 Expects screening and enrollment in RESTORE-1 trial of VY-AADC (NBIb-1817) to resume during 2H 2020 Intends to submit Investigation
November 9, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2020 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis
September 15, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 14, 2020 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Comm
August 10, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37625 Voyag
August 10, 2020	EX-99.1	Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates Plans to present three-year Phase 1b results of VY-AADC (NBIb-1817) in patients with Parkinson’s disease at the Movement Disorder Society (MDS) Virtual Congres EXHIBIT 99.1 Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates Plans to present three-year Phase 1b results of VY-AADC (NBIb-1817) in patients with Parkinson’s disease at the Movement Disorder Society (MDS) Virtual Congress 2020 Expects screening and enrollment in RESTORE-1 trial of VY-AADC (NBIb-1817) to resume during 2H 2020 Intends to submit Investigatio
August 10, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2020 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commiss
August 3, 2020	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 28, 2020 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissio
June 9, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 4, 2020 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
May 6, 2020	EX-99.1	Voyager Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates Announced 14 presentations at upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting highlighting Huntington’s disease, ALS SOD1, vec EXHIBIT 99.1 Voyager Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates Announced 14 presentations at upcoming American Society of Gene and Cell Therapy (ASGCT) Virtual Annual Meeting highlighting Huntington’s disease, ALS SOD1, vectorized antibodies, novel capsids and manufacturing Formed new Scientific Advisory Board with industry-leading expertise Ended Q1 2020 wi
May 6, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2020 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commission
May 6, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2020. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number: 001-37625 Vo
April 22, 2020	DEF 14A	VYGR / Voyager Therapeutics, Inc DEF 14A - - DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14
March 19, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 16, 2020 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissi
March 19, 2020	EX-10.1	Lease Agreement, by and between the Registrant and HCP/King 75 Hayden LLC, dated March 16, 2020 EX-10.1 2 tm2012761d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 75 HAYDEN AVENUE LEXINGTON, MASSACHUSETTS 02421 LEASE SUMMARY SHEET Execution Date: March 16, 2020 Tenant: VOYAGER THERAPEUTICS, INC., a Massachusetts corporation Tenant’s Mailing Address Prior to Occupancy: 64 Sidney Street Cambridge, Massachusetts 02139 Landlord: HCP/KING 75 HAYDEN LLC, a Delaware limited liability company Building: 75 Ha
March 5, 2020	SC 13G	VYGR / Voyager Therapeutics, Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
March 3, 2020	EX-4.4	Description of Registrant’s Securities EX-4.4 2 ex-4d4.htm EX-4.4 Exhibit 4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT General The following description of Voyager Therapeutics, Inc. (“us”, “our” or “we”), capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our Amended and Restated
March 3, 2020	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Entity State/Country of Organization Voyager Securities Corporation Massachusetts
March 3, 2020	S-8	Form S-8, File No. 333-236870 As filed with the Securities and Exchange Commission on March 3, 2020 Registration No.
March 3, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 3, 2020 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commissio
March 3, 2020	EX-99.1	Voyager Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates Protocol amendment being implemented for ongoing RESTORE-1 trial of VY-AADC (NBIb-1817) for Parkinson’s disease; plan to initiate RESTORE-2 trial EXHIBIT 99.1 Voyager Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates Protocol amendment being implemented for ongoing RESTORE-1 trial of VY-AADC (NBIb-1817) for Parkinson’s disease; plan to initiate RESTORE-2 trial in 2H 2020 Update on VY-HTT01 for Huntington’s disease preclinical program expected in 2Q 2020 Strong financial position with ~$282M of
March 3, 2020	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37625 Voyager Therapeutics, Inc.
February 14, 2020	SC 13G/A	VYGR / Voyager Therapeutics, Inc / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2020	SC 13G/A	VYGR / Voyager Therapeutics, Inc / Partner Fund Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Voyager Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2019 Date of Event Which Req
February 14, 2020	SC 13G/A	VYGR / Voyager Therapeutics, Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* VOYAGER THERAPEUTICS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to w
February 14, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 12, 2020 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commi
February 14, 2020	EX-10.1	Transition, Separation and Release Agreement, by and between the Registrant and Matthew P. Ottmer, dated February 12, 2020 Exhibit 10.1 EXECUTION VERSION TRANSITION, SEPARATION AND RELEASE AGREEMENT This Transition, Separation and Release of Claims Agreement (the “Agreement”) is made as of the Agreement Effective Date (as defined below) by and between Voyager Therapeutics, Inc. (the “Company”) and Matthew P. Ottmer (“Executive”) (together, the “Parties”). WHEREAS, the Company and Executive are parties to the Employmen
February 11, 2020	SC 13G/A	VYGR / Voyager Therapeutics, Inc / UBS Group AG - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Voyager Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 92915B106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t
February 11, 2020	SC 13G	VYGR / Voyager Therapeutics, Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Voyager Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 92915B106 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b)
December 3, 2019	424B3	Up to $100,000,000 Common Stock Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No.
November 27, 2019	CORRESP	VYGR / Voyager Therapeutics, Inc CORRESP - - VOYAGER THERAPEUTICS, INC. 75 Sidney Street Cambridge, MA 02139 November 27, 2019 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Voyager Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-234527 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities A
November 22, 2019	CORRESP	VYGR / Voyager Therapeutics, Inc CORRESP - - November 22, 2019 By Electronic Submission Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
November 6, 2019	S-3	VYGR / Voyager Therapeutics, Inc S-3 - - S-3 Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on November 6, 2019 Registration No.
November 6, 2019	EX-4.7	Form of Senior Note EX-4.7 5 a2239984zex-47.htm EX-4.7 Exhibit 4.7 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE D
November 6, 2019	EX-4.6	Form of Subordinated Indenture Exhibit 4.6 VOYAGER THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02
November 6, 2019	EX-1.2	Sales Agreement, by and between the Registrant and Cowen and Company, LLC, dated November 5, 2019 EX-1.2 2 a2239984zex-12.htm EX-1.2 Exhibit 1.2 Execution Version VOYAGER THERAPEUTICS, INC. $100,000,000 COMMON STOCK SALES AGREEMENT November 6, 2019 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Voyager Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1.
November 6, 2019	EX-4.8	Form of Subordinated Note Exhibit 4.8 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE
November 6, 2019	EX-4.5	Form of Senior Indenture EX-4.5 3 a2239984zex-45.htm EX-4.5 Exhibit 4.5 VOYAGER THERAPEUTICS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4
November 6, 2019	EX-99.1	Voyager Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Highlights EX-99.1 2 ex-99d1.htm EX-99.1 EXHIBIT 99.1 Voyager Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Highlights CAMBRIDGE, Mass., November 6, 2019 – Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its third quarter 2019 financial results, program
November 6, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2019 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37625 46-3003182 (State or other jurisdiction of incorporation) (Commis
November 6, 2019	EX-10.1	Amendment No. 1 to Consulting Agreement, by and between the Corporation and Steven M. Paul, M.D., dated July 9, 2019. Exhibit 10.1 AMENDMENT No. 1 CONSULTING AGREEMENT This Amendment No. 01 (“Amendment”) is entered into as of July 9, 2019 (the “Amendment Effective Date”) between Steven M. Paul, M.D. (“Company”) and Voyager Therapeutics, Inc. (“Voyager”) and relates to the Agreement referred to below. WHEREAS, the parties previously entered into a CONSULTING AGREEMENT, effective August 2, 2018 (the “Agreement”); a
November 6, 2019	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒▪ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2019. ☐▪ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number: 001-37
November 6, 2019	EX-10.2	Amendment No. 1 to the Consulting Agreement, by and between the Registrant and Dinah Sah, Ph.D., dated September 16, 2019 Exhibit 10.2 AMENDMENT No. 1 CONSULTING AGREEMENT This Amendment No. 01 (“Amendment”) is entered into as of September 16, 2019 (the “Amendment Effective Date”) between Dinah Sah (“Consultant”) and Voyager Therapeutics, Inc. (“Voyager”) and relates to the Agreement referred to below. WHEREAS, the parties previously entered into a CONSULTING AGREEMENT, effective June 28, 2019 (the “Agreement”); and
August 9, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 f8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2019 Voyager Therapeutics, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-37625 46-3003182 (State or other jurisdiction of incor
August 9, 2019	EX-99.1	Voyager Therapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights Gained worldwide rights to VY-HTT01 for Huntington’s disease, expanding wholly-owned pipeline Presented additional Phase 1b results for VY-AADC in patients wi EXHIBIT 99.1 Voyager Therapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights Gained worldwide rights to VY-HTT01 for Huntington’s disease, expanding wholly-owned pipeline Presented additional Phase 1b results for VY-AADC in patients with Parkinson’s disease at the 2019 American Academy of Neurology (AAN) Annual Meeting Strengthened leadership team with appointment of Om
August 9, 2019	EX-10.3	Termination Agreement, by and between the Registrant and Genzyme Corporation, dated June 14, 2019 Exhibit 10.3 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. TERMINATION AGREEMENT This TERMINATION AGREEMENT (the “Agreement”), is entered into as of June 14, 2019 (the “Agreement Date”), to terminate that certain Collaboratio

VYGR / Voyager Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings

MX:VYGR
DE:VT6	€ 3.18